Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Venus Medtech (Hangzhou)'s enterprise value is $33.74 Mil.
Venus Medtech (Hangzhou)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-40.92 Mil. Therefore, Venus Medtech (Hangzhou)'s EV-to-EBITDA for today is -0.82.
The historical rank and industry rank for Venus Medtech (Hangzhou)'s EV-to-EBITDA or its related term are showing as below:
VMTHF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -196.06 Med: -4.19 Max: -0.65
Current: -0.82
During the past 9 years, the highest EV-to-EBITDA of Venus Medtech (Hangzhou) was -0.65. The lowest was -196.06. And the median was -4.19.
VMTHF's EV-to-EBITDA is ranked worse than 100% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.37
vs VMTHF: -0.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Venus Medtech (Hangzhou)'s PE Ratio (TTM) for today is calculated as:
Venus Medtech (Hangzhou)'s share price for today is $0.4219.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.131.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s EV-to-EBITDA falls into.
Venus Medtech (Hangzhou)'s current Enterprise Value is $33.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-40.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) (VMTHF) has a EV-to-EBITDA of -0.82 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Venus Medtech (Hangzhou). According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #999999 out of 512 companies in the Medical Devices & Instruments industry.
Is Venus Medtech (Hangzhou)'s EV-to-EBITDA too high?
Venus Medtech (Hangzhou)'s current EV-to-EBITDA is -0.82. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #999999 out of 512 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #999999 out of 512 companies for EV-to-EBITDA. This places Venus Medtech (Hangzhou) in the lower half of its industry. The industry median EV-to-EBITDA is 14.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.37, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Venus Medtech (Hangzhou). For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current EV-to-EBITDA is -0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current EV-to-EBITDA of -0.82. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current EV-to-EBITDA is -0.82. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current EV-to-EBITDA is -0.82 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.
Key valuation signals for VMTHF:
EV-to-EBITDA: -0.82
GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for VMTHF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMTHF has been successfully added to your 
